fenoldopam has been researched along with Chronic Kidney Failure in 10 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results show that for advanced chronic renal failure, fenoldopam has diuretic and natriuretic properties that could be of clinical relevance." | 1.28 | Diuretic and natriuretic properties of fenoldopam in chronic renal failure. ( Alcázar, JM; Alvarez, C; Andrés, A; García-Robles, R; Martínez, J; Oliet, A; Rodicio, JL; Ruilope, LM; Sancho, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stone, GW | 1 |
| McCullough, PA | 1 |
| Tumlin, JA | 1 |
| Lepor, NE | 1 |
| Madyoon, H | 1 |
| Murray, P | 1 |
| Wang, A | 1 |
| Chu, AA | 1 |
| Schaer, GL | 1 |
| Stevens, M | 1 |
| Wilensky, RL | 1 |
| O'Neill, WW | 1 |
| Cohen, MG | 1 |
| Ng, MK | 1 |
| Tremmel, J | 1 |
| Fitzgerald, PJ | 1 |
| Fearon, WF | 1 |
| Barr, LF | 1 |
| Kolodner, K | 1 |
| Robles, RG | 1 |
| Villa, E | 1 |
| Andres, A | 2 |
| Martinez, J | 2 |
| Ruilope, LM | 2 |
| Sancho, JM | 1 |
| Kini, AS | 1 |
| Mitre, CA | 1 |
| Kamran, M | 1 |
| Suleman, J | 1 |
| Kim, M | 1 |
| Duffy, ME | 1 |
| Marmur, JD | 1 |
| Sharma, SK | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Smit, AJ | 2 |
| de Fijter, CW | 1 |
| Comans, EF | 1 |
| de Vries, PM | 1 |
| Oe, PL | 1 |
| Roos, JC | 1 |
| Streurman, O | 1 |
| Donker, AJ | 1 |
| Brooks, DP | 1 |
| Goldstein, R | 1 |
| Koster, PF | 1 |
| DePalma, PD | 1 |
| DiCristo, M | 1 |
| Karpinski, K | 1 |
| Hyneck, M | 1 |
| García-Robles, R | 1 |
| Alcázar, JM | 1 |
| Alvarez, C | 1 |
| Oliet, A | 1 |
| Sancho, J | 1 |
| Rodicio, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.[NCT00122018] | Phase 2 | 80 participants | Interventional | 2002-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
| Intervention | participants (Number) |
|---|---|
| Systemic Alone Therapy Group | 146 |
| RenalGuard System Group | 146 |
2 trials available for fenoldopam and Chronic Kidney Failure
| Article | Year |
|---|---|
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Contrast Media; Creatinine; Dopamine Agoni | 2003 |
N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery.
Topics: Acetylcysteine; Aged; Cardiac Surgical Procedures; Dopamine Agonists; Double-Blind Method; Female; F | 2008 |
8 other studies available for fenoldopam and Chronic Kidney Failure
| Article | Year |
|---|---|
First experience with intra-renal fenoldopam in a patient with heart failure.
Topics: Aged; Cardiac Catheterization; Catheterization; Electrocardiography; Equipment Design; Equipment Saf | 2005 |
Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy.
Topics: Acute Kidney Injury; Catheterization; Contrast Media; Fenoldopam; Humans; Kidney Failure, Chronic; M | 2006 |
Natriuretic effects of dopamine agonist drugs in models of reduced renal mass.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Animals; Blood Pressure; Di | 1993 |
Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
Topics: Aged; Atherectomy, Coronary; Cardiac Catheterization; Contrast Media; Diabetic Nephropathies; Dopami | 2002 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Aldos | 1990 |
Effect of fenoldopam in dogs with spontaneous renal insufficiency.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Animals; Creatinin | 1990 |
Diuretic and natriuretic properties of fenoldopam in chronic renal failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Blood Pressure; Diuresis; Dopamine Agent | 1989 |